Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.44 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1026186 | 0.92 | FFAR4 (0.54) | FFAR4SIGMAR1CHRM4POLBKDM4E | |
| SCHEMBL9176367 | 0.81 | KDM4E (0.53) | SIGMAR1CHRM4POLBKDM4ETP53 | |
| SCHEMBL7753345 | 0.81 | USP14 (0.52) | FFAR4SIGMAR1CHRM4KDM4ETP53 | |
| SCHEMBL2557268 | 0.81 | FFAR4 (0.61) | FFAR4CHRM4 | |
| SCHEMBL321690 | 0.80 | NOTUM (0.58) | CHRM4POLBKDM4ETP53DPP4 | |
| SCHEMBL132858 | 0.80 | FFAR4 (0.53) | FFAR4POLBKDM4ETP53SYK | |
| SCHEMBL26373077 | 0.80 | FFAR4 (0.55) | FFAR4 | |
| SCHEMBL20271745 | 0.80 | NOTUM (0.56) | FFAR4SIGMAR1CHRM4POLBKDM4E | |
| SCHEMBL20271742 | 0.80 | NOTUM (0.56) | FFAR4 | |
| SCHEMBL13622620 | 0.80 | KCNH2 (0.55) | CHRM4DPP4USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| CN-1076345-C | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 2001-12-19 | — | — | CN | disclosed |
| EP-0725059-B1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMA (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-6048854-A | ANTICOAGULANTS; ANTICANCER AGENT; WOUND HEALING AGENTS;BONE DISORDERS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-04-11 | — | — | US | disclosed |
| US-5707994-A | USEFUL AS A PLATELET AGGREGATION INHIBITOR, CANCER METASTASIS INHIBITOR, WOUND HEALING AGENT OR A BONE RESORPTION INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| CN-1138322-A | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0725059-A1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR4 2075/4885SIGMAR1 3483/4885CHRM4 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.